Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Carparts.Com Inc (PRTS) vs Sana Biotechnology Inc (SANA) Price & Performance

Carparts.Com IncTrade
Sana Biotechnology IncTrade

Price performance (Past 24H)

Key statistics

Carparts.Com Inc vs Sana Biotechnology Inc — how do they compare? Carparts.Com Inc trades at $10.22 (market cap $72.26M), while Sana Biotechnology Inc trades at $3.24 (market cap $1.03B). The key difference: Sana Biotechnology Inc is far larger — about 14.3× Carparts.Com Inc's market cap, and Carparts.Com Inc is trading nearer its 52-week high, Sana Biotechnology Inc nearer its low. Which is the better fit depends on your goals.

PRTSSANA
Market Cap
$72.26M$1.03B
Sector
Consumer CyclicalHealth
52-Week High
$10.00$5.92
52-Week Low
$3.88$2.68
Enterprise Value
$85.23M$946.04M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Carparts.Com Inc

CarParts.com (PRTS) trades at $9.50, up 2.15% with strong technical momentum and bullish moving average signals. The company shows improving quarterly earnings performance with three consecutive beats, though it remains unprofitable with negative margins. Recent developments include a new $25 million credit facility and Nasdaq compliance restoration, while analyst sentiment leans positive with 60% buy ratings.

The outlook suggests cautious optimism given improving earnings trajectory and technical strength, but significant risks persist from sustained losses, negative cash flow, and competitive pressures. Investment appeal hinges on the company's ability to translate revenue stabilization into profitability while managing operational challenges in the automotive e-commerce sector.

Sana Biotechnology Inc

SANA Biotechnology trades at $3.45, down 10.39% in the past 24 hours, reflecting bearish technical signals and negative profitability. The company reported a net loss of $244.17 million for 2025, with a price-to-book ratio of 6.68. Recent news includes investor conference presentations and a peer-reviewed publication in The New England Journal of Medicine highlighting clinical data.

Despite analyst consensus favoring a 'Buy' rating (81.82% of 11 analysts), the stock faces significant risks from negative cash flows, high losses, and potential fiduciary concerns. Upside hinges on successful clinical developments and improved financial performance, but current fundamentals suggest caution for investors.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Carparts.Com Inc

CarParts.com Inc is an online provider of automotive aftermarket parts and repair information. The company principally sells its products to individual consumers through its network of websites and online marketplaces. The company's products consist of collision parts serving the body repair market, engine parts to serve the replacement parts market, and performance parts and accessories.

Read more on PRTS

About Sana Biotechnology Inc

Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.

Read more on SANA